All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
The all Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the all Hub cannot guarantee the accuracy of translated content. The all and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer and supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View all content recommended for you
Interfant-06 study: Why should we assess end-of-consolidation MRD in infants with ALL?
Featured:
Janine StutterheimDuring the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the ALL Hub spoke to Janine Stutterheim, Princess Máxima Center, Utrecht, NL. We asked, Why should we assess end-of-consolidation measurable residual disease (MRD) in infants with ALL?
Interfant-06 study: Why should we assess end-of-consolidation MRD in infants with ALL?
In this podcast, Stutterheim discusses the prognostic value of MRD for survival outcomes at the end of consolidation in infants with ALL. She also discusses the predictive value of MRD status at the end of induction of therapy for selecting different consolidation therapies. Finally, she reports the relationship of MRD status at the end of induction with myeloid markers in the context of selecting myeloid-style therapy.
Your opinion matters
On average, how many patients with B-cell acute lymphoblastic leukemia do you see in a year?